Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Park Doctrine Influence Could Wane In Upcoming Cases, Attorney Argues

This article was originally published in The Tan Sheet

Executive Summary

As penalties increase under the responsible corporate officer doctrine, attorney Allison Burroughs says to expect increased scrutiny. A DoJ Consumer Protection Branch official says pharma execs will be held responsible because of the role the industry plays in consumers’ daily lives.

You may also be interested in...



FDA Posts Criteria For Targeting Executives As Responsible Officers

FDA publishes criteria for filing criminal misdemeanor charges against executives from firms that break food and drug laws almost a year after the agency signaled its intent to pursue such cases.

Still Guilty: Three Former Purdue Execs Lose Fight To Overturn Their Exclusion From Gov't Programs

"As with plaintiffs' repeated attempts to characterize themselves as innocent third parties to Purdue's misbranding, the court finds plaintiffs' arguments with respect to financial loss reflective of a fundamental misconception of their own plea agreements," the ruling states.

FDA's Executive Responsibility Policy Could Sweep Up Board Members

Add board members to the list of company executives who could be personally affected by FDA's plans to focus on responsible individuals in the corporations it takes to task as part of its enforcement mission

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel